Core Insights - Lexicon Pharmaceuticals presented new clinical data on sotagliflozin at the AHA Annual Scientific Sessions 2025, highlighting its benefits for heart failure patients with preserved ejection fraction (HFpEF) [1][5] - The study demonstrated significant improvements in cardiac structure, function, quality of life, and functional capacity for HFpEF patients without diabetes [4][5] Study Details - The "SOTA P CARDIA" trial was a randomized, double-blind, placebo-controlled study directed by Dr. Juan J Badimon, focusing exclusively on HFpEF patients [2] - The study enrolled 88 diverse participants, with 70% being female, and compared the effects of sotagliflozin against a placebo over six months [3] Key Findings - Treatment with sotagliflozin resulted in statistically significant improvements in left ventricular mass, diastolic function, six-minute walk test capacity, and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores [4] - Although peak VO2 improvement was not statistically significant, there was a notable enhancement observed post-treatment [4] Broader Implications - The findings suggest that sotagliflozin may represent a new class of medication for HFpEF patients, particularly given its potential to reduce risks for major adverse cardiovascular events (MACE) and rehospitalization [6] - Approximately 6.7 million Americans suffer from heart failure, with over half having preserved ejection fraction, indicating a significant patient population that could benefit from sotagliflozin [5] About Sotagliflozin - Sotagliflozin is an oral inhibitor of SGLT2 and SGLT1, involved in glucose regulation, and has been studied in various patient populations, including those with heart failure, diabetes, and chronic kidney disease [7] - The drug is also under investigation for hypertrophic cardiomyopathy (HCM) [7] Company Overview - Lexicon Pharmaceuticals aims to pioneer transformative medicines through its Genome5000™ program, focusing on genomics and the discovery of therapeutic protein targets [8] - The company has a pipeline of drug candidates in various stages of development, targeting conditions such as neuropathic pain, HCM, obesity, and metabolism [9]

Core Insights - Lexicon Pharmaceuticals is presenting data on diabetic peripheral neuropathic pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience, highlighting the impact of DPNP on patients despite standard treatments [1][2] - Approximately 9 million patients in the U.S. suffer from DPNP, affecting 30% of type 1 diabetes patients and 50% of type 2 diabetes patients [2] - The study aims to raise awareness among healthcare professionals about the burden of DPNP on patients and encourage discussions about treatment options [3] Product Development - Pilavapadin (LX9211) is an investigational, non-opioid treatment for DPNP, discovered through Lexicon's gene science approach, targeting AAK1 to inhibit pain signaling without affecting opiate pathways [4] - The Phase 2a proof-of-concept RELIEF-DPN-1 study demonstrated that pilavapadin met its primary endpoint by reducing average daily pain scores (ADPS) at week 6 compared to placebo, showing significant benefits in alleviating DPNP symptoms [5] - Pilavapadin has received Fast Track designation from the U.S. FDA for its development in treating DPNP [5] Company Overview - Lexicon Pharmaceuticals focuses on pioneering medicines that transform patients' lives, utilizing its Genome5000™ program to identify therapeutic protein targets across various diseases [6] - The company has a pipeline of drug candidates in clinical and preclinical development for conditions including neuropathic pain, hypertrophic cardiomyopathy, and obesity [6]